분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2015-01-07 01:05:18 , Hit : 1235
 Janssen, Isis Pharma Ink Up-to-$835M Antisense Agreement


GEN News Highlights
More »
Jan 5, 2015

Johnson & Johnson’s Janssen Biotech will use Isis Pharmaceuticals’ RNA-targeted technology platform to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract, in a partnership that could generate up to $835 million for Isis.

The collaboration will also bring Isis Pharma access to Janssen’s expertise in autoimmune disorders and therapeutic formulation toward development of antisense drugs to treat autoimmune disorders in the GI tract through oral delivery and other forms of local administration.

Janssen’s expertise includes its already-marketed intravenous drug Remicade (infliximab), a tumor necrosis factor (TNF) inhibitor that is indicated for a variety of disorders—including Crohn’s disease in children and adults, ulcerative colitis in children and adults, rheumatoid and psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.

Remicade is a blockbuster for Janssen and parent Johnson & Johnson. During the first nine months of 2014, Remicade racked up $5.196 billion in sales, up 4.7% from Q1-Q3 2013.

“This collaboration broadens the utility of our drug discovery technology to new targets in the GI tract and expands the administration of antisense drugs to local delivery, including oral delivery, to the gut," B. Lynne Parshall, Isis Pharma’s COO, said in a statement.

The collaboration agreement covers three development programs. Janssen agreed to pay Isis Pharma $35 million upfront, including a payment to initiate human lead optimization on the first collaboration target.

Isis Pharma said it is eligible for another nearly $800 million in development, regulatory, and sales milestone payments, as well as license fees for these programs. Isis will also receive tiered royalties averaging double-digits on sales from any product that is successfully commercialized.

In return, Janssen has the option to license a drug from each of the programs once a development candidate is identified. If Janssen exercises its option, it will assume global development, regulatory, and commercialization responsibilities, Isis Pharma said.

Antisense drugs are small (12-21 nucleotides) DNA- or RNA-like compounds that are chemically modified to engineer favorable drug properties. Isis Pharma’s platform is designed to develop antisense drugs that interact precisely with their targets, namely specific sequences of RNA. According to Isis, many of the antisense drugs in its pipeline bind to messenger RNAs (mRNAs), and inhibit the production of disease-causing proteins.

The collaboration aims to expand Isis Pharma’s pipeline, now consisting of 34 drugs for treating  a variety of diseases within its key therapeutic areas of cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. Isis’ lead product—Kynamro, for treatment of patients with homozygous FH—is being commercialized in the U.S. and other countries through the Sanofi subsidiary Genzyme.

Isis Pharma’s collaboration with Janssen comes less than two months after the company agreed to expand its nearly two-year-old research collaboration with AstraZeneca by launching a strategic alliance to discover and develop new delivery methods for antisense oligonucleotides. The value of that expanded collaboration was not disclosed.








1087   “Kissing Disease” Virus Promotes Malignant Breast Cancer Development  이성욱 2016/08/03 1188
1086   에볼라 확산원인에 대한 새로운 주장  이성욱 2015/01/06 1189
1085   생명과학 연구에서 암컷쥐가 필요한 이유  이성욱 2015/07/23 1190
1084   융합연구리뷰 | Convergence Research Review  이성욱 2016/01/08 1191
1083   인류의 역사를 고스란히 보여주는 결핵균의 게놈  이성욱 2015/01/21 1201
1082   [바이오토픽] 브로드 연구소, 열띤 CRISPR 특허전쟁에서 승리  이성욱 2017/02/16 1206
1081   유전자치료제 연구개발 및 규제 동향 2015-식품의약품안전처  이성욱 2016/01/20 1209
1080   의문이 제기된 `젊은 피`의 항노화 효과  이성욱 2015/05/22 1210
1079   Cost to Develop a Drug More Than Doubles to $2.56 Billion  이성욱 2014/11/21 1218
1078   FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1222
1077   정밀의학의 끝: 개인화된 종양백신을 개발하는 과학자들  이성욱 2016/04/26 1222
1076   Gilead wins European approval of next-generation hepatitis C drug  이성욱 2014/11/20 1223
1075   특허전쟁: 미국 특허청, CRISPR의 특허권 중재 시작  이성욱 2016/03/08 1225
1074   미국 과학·공학·의학 아카데미, 「GM 베이비」의 진행방향에 대한 윤곽 발표  이성욱 2017/02/16 1225
1073   세계 20여 개국 과학자들, 유전자편집 정상회담 개최  이성욱 2015/12/05 1226
1072   CRISPR의 능력을 배가(倍加)시키는 미니 유전자  이성욱 2015/04/02 1233
  Janssen, Isis Pharma Ink Up-to-$835M Antisense Agreement  이성욱 2015/01/07 1235
1070   줄기세포로 만든 초기 난자와 정자  이성욱 2014/12/31 1238
1069   맹인을 위한 유전자치료의 쇠퇴  이성욱 2015/05/08 1244
1068   유전자편집치료에 희망을 준 백혈병치료  이성욱 2015/11/11 1246

[1][2][3][4][5][6][7][8][9] 10 ..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN